May 26 (Reuters) - The U.S. Food and Drug administration on Wednesday gave an emergency use authorization to the COVID-19 antibody treatment developed by Vir Biotechnology Inc and GlaxoSmithKline. (https://bit.ly/3uorQZ8) (Reporting by Amruta Khandekar; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,734 GBX | +0.29% | +4.87% | +19.54% |
03/05 | GSK : DZ Bank remains Neutral | ZD |
03/05 | GSK plc : Back on track |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.54% | 88.72B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- GlaxoSmithKline : U.S. FDA gives emergency use approval to GSK-Vir COVID-19 antibody drug